Canada Pension Plan Investment Board Boosts Stake in Amgen Inc. (AMGN)
Canada Pension Plan Investment Board grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 65.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,706,261 shares of the medical research company’s stock after acquiring an additional 676,300 shares during the quarter. Canada Pension Plan Investment Board owned 0.23% of Amgen worth $293,869,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of AMGN. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 4 shares in the last quarter. American Beacon Advisors Inc. acquired a new position in shares of Amgen in the first quarter valued at $106,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new position in shares of Amgen in the first quarter valued at $121,000. 78.08% of the stock is owned by institutional investors.
Amgen Inc. (NASDAQ:AMGN) opened at 184.12 on Friday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The firm’s 50-day moving average price is $184.98 and its 200-day moving average price is $171.46. The company has a market cap of $134.35 billion, a PE ratio of 16.77 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
A number of research analysts recently commented on the company. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday. Jefferies Group LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research note on Tuesday, July 11th. Barclays PLC increased their price objective on Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. BMO Capital Markets reiterated a “hold” rating and set a $199.00 price objective on shares of Amgen in a research note on Monday, September 25th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $186.00 price objective (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $189.99.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.